MedTrace Logo

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

NCT03818880 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-05

No results posted yet for this study

Summary

Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

Conditions

  • Myopia, Progressive

Interventions

DEVICE

Novel spectacle lens design

Spectacle lens to control progression of myopia

Sponsors & Collaborators

  • University of Waterloo

    collaborator OTHER

  • SightGlass Vision, Inc.

    lead INDUSTRY

Principal Investigators

  • Lyndon Jones, PhD, FCOptom · Centre for Ocular Research & Education, Canada

  • Jill Woods, BSc, MCOptom · Centre for Ocular Research & Education, Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2022-04-21
Completion
2026-12-31
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03818880 on ClinicalTrials.gov